This supplement is based on two symposia sponsored by Glaxo Wellcome. The first was on Monotherapy and Polytherapy in Epilepsy held at the 32nd Canadian Congress of Neurological Sciences in Saskatoon, Saskatchewan in June, 1997. The second was a continuing medical education program for neurologists on epilepsy held at Glaxo Wellcome offices in Mississauga, Ontario in September, 1997.
|